ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Merck To Pay $321.6 Million Fine For Illegal Marketing Of Vioxx

DOW JONES NEWSWIRES A U.S. district court judge in Boston ordered Merck & Co. (MRK) to pay a $321.6 million criminal fine for its violation of a federal drug law in connection with its marketing of the former painkiller Vioxx. In December, Merck pleaded guilty to violating the Federal Food, Drug, and Cosmetic Act for introducing a misbranded drug into interstate commerce. The company said it previously recorded a $950 million charge in October 2010 in anticipation of the settlement, which resolves a seven-year investigation. Merck withdrew Vioxx from the market in 2004 after it was linked to a higher risk of heart attacks and strokes. "The government recognized Merck's full cooperation with its investigation and by putting this long-standing investigation to rest, we can more fully focus on discovering, developing and providing innovative medicines and vaccines that save and improve lives around the world," Merck said in a statement. In November, Merck had agreed to pay $950 million and plead guilty to a misdemeanor charge of marketing a misbranded drug, to resolve government allegations that the company illegally promoted Vioxx and deceived the government about the drug's safety. The government alleged that Merck promoted Vioxx for treatment of rheumatoid arthritis before that use was approved by regulators. A portion of the $950 million settlement also was to resolve parallel civil allegations that Merck made false and misleading statements about Vioxx's safety, causing government health programs to pay for the drug's use. Merck denied the civil allegations. Shares were off 14 cents to $38.26 in recent trading. The stock is up 1.5% since the start of the year. -By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com

Stock News for Merck (MRK)
DateTimeHeadline
09/23/201609:41:00Merck's Keytruda Finds Fast Entry Into China Via Medical-Tourism...
09/23/201608:00:00Merck to Hold Third-Quarter 2016 Sales and Earnings Conference...
09/20/201608:30:00Merck to Host Investor Teleconference to Discuss ESMO 2016 Highlights
09/20/201603:03:00Business Watch -- WSJ
09/19/201611:49:00Sanofi Files Suit Against Merck, Claiming Patent Infringements...
09/19/201608:30:00Sanofi Files Suit Against Merck
09/19/201608:14:00Sanofi Files Suit Against Merck on Patent Infringements -Update
09/19/201602:08:00Sanofi Files U.S. Suit Against Merck on Patent Infringements
09/15/201610:03:00Merck, Pfizer Diabetes Therapy Meets Late-Stage Study Goals
09/13/201622:30:00Obama Administration Makes Last-Ditch Push for Trade Vote
09/13/201609:00:00Merck Publishes 2015/2016 Global Corporate Responsibility Report
09/13/201603:15:00Merck's Consumer Health Business Presents New Purpose to Help...
09/12/201608:00:00New Biosimilar can Offer an Effective and Lower Cost Treatment...
09/12/201608:00:00Un nouveau produit biosimilaire peut offrir une option thérapeutique...
09/09/201608:00:00Merck to Participate at the Morgan Stanley Global Healthcare...
09/08/201603:04:00Business Watch -- WSJ
09/07/201614:42:00FDA to Review Merck Drug as First-Line Treatment for Lung Cancer
09/07/201608:50:00FDA to Review Merck's Keytruda as First-Line Treatment for Lung...
09/07/201606:45:00FDA Accepts Supplemental Biologics License Application, Assigns...
09/02/201609:42:00U.S. Hot Stocks: Hot Stocks to Watch

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad